Oncotarget is a medical journal that focuses on research in the field of oncology. The journal is published every week by Impact Journals. It is licensed under Creative Commons Attribution as an open access journal and is highly rated by the Journal Citation Reports. Recently, the journal started publishing papers on other topics like Neuroscience, Cardiology, Cell Biology, Pharmacology, Metabolism, and Endocrinology.
The Editorial Team
Oncotarget boasts an experienced editorial team that comprises of the editors-in-chief Andrei V. Gudkov and Mikhail V. Blagosklonny, both from the Roswell Park Cancer Institute. Other members of the editorial board include Fredrick Alt & Arthur B. Pardee from Harvard Medical School, Carlo M. Croce from Ohio State University, Ronald A. DePinho from The University of Texas, and Alexander Varshavsky from California Institute of Technology.
Under the leadership of the experienced editorial team, Oncotarget aims at eliminating human diseases. With its free-access, the Journal breaks the barrier between medical specialties and makes scientific research widely and readily available.
Social Media Presence
In the recent past, organizations have started using the social media platforms to reach out to a wider audience. Oncotarget has not been left behind in these new developments, having opened Twitter, Facebook, YouTube, and Google Plus accounts. Their twitter handle is @OncotargetJrnl, their Facebook profile name is Oncotarget, and their YouTube channel is Oncotarget Journals. In all these social media platforms, they post content covered in their journals, both in writing and in videos. Oncotarget is published by Impact Journals
About Andrei Gudkov
Prof. Andrei V. Gudkov is a co-chief-editor of Oncotarget. Being a professor at Roswell Park Cancer Institute, Andrei serves as the senior VP for Basic Research in the institution, with an emphasis on gene & drug discovery for cancer treatment. He studied experimental oncology at National Cancer Center, USSR and Molecular Biology from Moscow State University, USSR. Andrei is a co-founder of Cleveland BioLabs, Inc.
About Mikhail Blagosklonny
Prof. Mikhail V. Blagosklonny is a co-chief-editor of Oncotarget. He is a professor at New York’s Roswell Park Cancer Institute. He is interested in researches on molecular biology, clinical investigation, and cellular biology. Mikhail boasts more than 250 articles to his name as well as being an Associate Editor for several publications. He was the Editor-in-Chief of Cell Cycle.
Follow Oncotarget journal on Twitter.